Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
Status: | Recruiting |
---|---|
Conditions: | Skin Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 19 - Any |
Updated: | 12/21/2018 |
Start Date: | April 26, 2017 |
End Date: | April 26, 2021 |
Contact: | Rosaura Diaz |
Email: | Rosaura.diaz@med.usc.edu |
Phone: | 323-442-7469 |
Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma
This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting
sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that
may make it easier to see if the tumor cells have spread to the sentinel lymph node using an
ultrasound.
sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that
may make it easier to see if the tumor cells have spread to the sentinel lymph node using an
ultrasound.
PRIMARY OBJECTIVES:
I. To study the imaging feasibility of peri-tumoral administration of sonazoid ultrasound
contrast agent for assessment of sentinel lymph node (SLN) detection in melanoma.
II. To compare SLN detection between sonazoid ultrasound and standard of care (SOC)
technique.
SECONDARY OBJECTIVES:
I. To assess the sonazoid ultrasound (US) imaging appearance of lymph nodes which are shown
to be involved with metastatic disease.
OUTLINE:
Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging. Patients also
undergo standard of care sentinel lymph node biopsy (SLNB).
After completion of study treatment, patients are followed up at 24 and 48 hours.
I. To study the imaging feasibility of peri-tumoral administration of sonazoid ultrasound
contrast agent for assessment of sentinel lymph node (SLN) detection in melanoma.
II. To compare SLN detection between sonazoid ultrasound and standard of care (SOC)
technique.
SECONDARY OBJECTIVES:
I. To assess the sonazoid ultrasound (US) imaging appearance of lymph nodes which are shown
to be involved with metastatic disease.
OUTLINE:
Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging. Patients also
undergo standard of care sentinel lymph node biopsy (SLNB).
After completion of study treatment, patients are followed up at 24 and 48 hours.
Inclusion Criteria:
- Cutaneous melanoma with Breslow depth > 1 mm or melanoma Breslow depth of 0.76 - 1.00
mm in setting of ulceration, extensive regression
- Mitotic rate >= 1/mm^2
- Presence of angiolymphatic invasion
- Deep positive margin
- No known allergies to contrast material
Exclusion Criteria:
- Pregnant or nursing
- Patients with known cardiac shunt
- Patients with class II heart failure or worse, per New York Heart Association (NYHA)
classification
- Patients who have experienced an acute coronary syndrome or angina in the past 6
months
- Patients who have undergone coronary artery bypass grafting (CABG) or coronary
stenting in the past 3 years
- Patients with evidence of moderate or severe cardiac valvular disease on
echocardiogram
- Patients with evidence of moderate or severe pulmonary hypertension on echocardiogram
- Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification
- Patients with hypersensitivity to sonazoid or one of its components
- Patients with hypersensitivity to egg or egg products, because sonazoid contains a
chicken egg-derived surfactant (hydrogenated egg phosphatidylserine sodium)
- Patients who cannot consent for themselves
We found this trial at
1
site
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Kevin King, MD
Phone: 323-442-7469
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials